Pulmatrix Stock Today
| PULM Stock | USD 6.64 0.70 9.54% |
Performance15 of 100
| Odds Of DistressOver 64
|
Pulmatrix is selling at 6.64 as of the 30th of November 2024; that is 9.54 percent decrease since the beginning of the trading day. The stock's lowest day price was 6.33. Pulmatrix has more than 64 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Pulmatrix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of March 2014 | Category Healthcare | Classification Health Care |
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. The company has 3.65 M outstanding shares of which 411.61 K shares are at this time shorted by private and institutional investors with about 0.75 trading days to cover. More on Pulmatrix
Moving together with Pulmatrix Stock
Moving against Pulmatrix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Pulmatrix Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Teofilo MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPulmatrix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pulmatrix's financial leverage. It provides some insight into what part of Pulmatrix's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pulmatrix (PULM) is traded on NASDAQ Exchange in USA. It is located in 36 Crosby Drive, Bedford, MA, United States, 01730 and employs 22 people. Pulmatrix is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.81 M. Pulmatrix conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 3.65 M outstanding shares of which 411.61 K shares are at this time shorted by private and institutional investors with about 0.75 trading days to cover.
Pulmatrix currently holds about 42.91 M in cash with (15.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Pulmatrix Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Pulmatrix is $26.81 Million. Roughly 92.84 pct. of Pulmatrix outstanding shares are held by general public with 7.16 (%) by third-party entities. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Pulmatrix Ownership Details
Pulmatrix Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Hanson Mcclain Inc | 2024-09-30 | 3.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Citigroup Inc | 2024-06-30 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | |
| Gradient Investments | 2024-09-30 | 0.0 | |
| Renaissance Technologies Corp | 2024-09-30 | 117.2 K | |
| Blackrock Inc | 54.9 K | ||
| Vanguard Group Inc | 2024-09-30 | 35.1 K | |
| Geode Capital Management, Llc | 29.6 K | ||
| State Street Corp | 2024-06-30 | 13.9 K | |
| Citadel Advisors Llc | 2024-09-30 | 10.3 K |
Pulmatrix Historical Income Statement
Pulmatrix Stock Against Markets
Pulmatrix Corporate Management
| MBA CMA | Interim Officer | Profile | |
| Alexander Klibanov | Founder | Profile | |
| Margaret MD | Chief Officer | Profile | |
| David JD | Advisor | Profile | |
| Aidan Curran | VP Affairs | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 3.119 | Quarterly Revenue Growth (0.16) | Return On Assets (0.30) | Return On Equity (0.59) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.